-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on BioCryst Pharma, Lowers Price Target to $17

Benzinga·11/05/2026 13:40:51
Listen to the news
Wedbush analyst Laura Chico maintains BioCryst Pharma (NASDAQ:BCRX) with a Outperform and lowers the price target from $18 to $17.